FILANA THERAPEUTICS, INC.

FILANA THERAPEUTICS, INC. Annual Report Summary for Fiscal Year Ended December 31, 2025

Dive into the financial health and strategic direction of FILANA THERAPEUTICS, INC. with this summary of its latest 10-K filing for the fiscal year ended December 31, 2025. This overview highlights critical aspects for potential investors.

1. Business Overview

FILANA THERAPEUTICS, INC. is a biotechnology company that focuses on discovering, developing, and commercializing novel therapeutic treatments. The company's pipeline centers around Simufilam, its lead investigational drug candidate.

• Business Focus: The company directs its efforts toward advancing Simufilam.
• Key Partnership: During fiscal year 2025 (FY2025), the company entered into a license agreement with Yale University.

2. Financial Performance

Understanding Filana's financial health and operational efficiency is critical for investors.

• Market Capitalization: As of June 30, 2025, Filana Therapeutics' market capitalization stood at approximately $87 million, with shares trading around $1.81.
• Shares Outstanding: The company had approximately 48.3 million shares outstanding as of March 9, 2026.
• Reporting Status: Classified as a "Smaller reporting company" and a "Non-accelerated filer," Filana has a smaller market capitalization and fewer reporting requirements than larger public companies.

3. Management's Discussion and Analysis of Financial Condition and Results of Operations (MD&A)

Management discusses the company's financial condition, changes, and operational results in this section.

• Workforce Reduction: In early 2025, the company implemented a workforce reduction.

4. Risk Factors

Investing in a biotechnology company carries inherent risks. Filana faces various risks that could materially affect its business, financial condition, and results of operations.

• Clinical Development Risk: Clinical trial failures pose a significant risk for Simufilam and other pipeline candidates, including potential delays, negative results, or an inability to secure regulatory approval. Drug development is lengthy and expensive, offering no guarantee that any product candidate will achieve commercial success.
• Regulatory Risk: Obtaining FDA or other regulatory approvals carries risks, including the lengthy and uncertain process, potential for unexpected requirements, and the possibility of post-market regulatory actions.
• Intellectual Property Risk: Risks relate to patent protection for Simufilam and other technologies, including potential infringement claims by third parties, challenges to existing intellectual property, or the inability to obtain or maintain adequate patent protection.
• Funding Risk: The company faces the risk of needing additional capital to fund operations and clinical trials. The uncertainty of obtaining such funding on favorable terms could lead to significant dilution for existing shareholders or an inability to continue operations.
• Competition: Competitors may develop superior or more cost-effective treatments for the same indications, potentially eroding market share or rendering Filana's product candidates obsolete.
• Legal and Litigation Risk: Ongoing lawsuits regarding Federal Securities Laws violations and Shareholder Derivative Actions pose significant financial and reputational risks with uncertain outcomes. These could result in substantial monetary damages, injunctions, or adverse publicity.
• Cybersecurity Risk: Despite the company's dedicated Director of IT and Board oversight for cybersecurity, the risk of data breaches, intellectual property theft, or operational disruption from cyberattacks remains a concern, particularly for a company handling sensitive data.

5. Future Outlook and Strategy

• Strategic Direction: The workforce reduction in early 2025 suggests a strategic adjustment, potentially focusing on cost efficiency or pipeline prioritization.
• Leadership and Corporate Governance: The company's focus on cybersecurity, with a dedicated Director of IT reporting to senior management and the Board, indicates a commitment to managing digital risks and protecting company information.

This summary provides a snapshot of Filana Therapeutics' current standing based on available information. Potential investors should conduct further due diligence to fully understand the company's prospects and risks.